Search Result

Results for "

β-amyloid peptides

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (71) Apoptosis (2) Beta-secretase (1) CaMK (1) Cholinesterase (ChE) (5) Drug Derivative (1) Endogenous Metabolite (1) Fluorescent Dye (2) Gap Junction Protein (1) GCGR (1) Isotope-Labeled Compounds (1) Monoamine Oxidase (2)
By Research Areas:	Metabolic Disease (1) Neurological Disease (74)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1363B

β-Amyloid (1-42), human, HFIP-treated 20+ Cited Publications	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide *that has been treated with HFIP from β-Amyloid* (1-42), human (HY-P1363A)*, is a brain-penetrant amyloid* protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363

β-Amyloid (1-42), human TFA 20+ Cited Publications amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363A

β-Amyloid (1-42), human 20+ Cited Publications amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P0128

β-Amyloid (25-35) Maximum Cited Publications 42 Publications Verification amyloid beta-peptide (25-35); Aβ25-35; β-amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P1388

β-Amyloid (1-42), (rat/mouse) 5+ Cited Publications amyloid β-peptide (1-42) (rat/mouse)	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P1362

β-Amyloid (42-1), human 1 Publications Verification amyloid β Peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease .

HY-P0128A

β-Amyloid (25-35), HFIP-treated Maximum Cited Publications 42 Publications Verification amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-amyloid peptide (25-35), HFIP-treated	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P1363F3

5-FAM-β-Amyloid (1-42), human Tris 5-FAM-amyloid β-peptide (1-42) (human) Tris	Amyloid-β	Neurological Disease
5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).

HY-P1466

β-Amyloid (1-16) amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1903

β-Amyloid (35-42)	Amyloid-β	Neurological Disease
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.

HY-P5124

β-Amyloid peptide(16-20) KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-P1363F1

Biotin-β-Amyloid (1-42), human TFA Biotin-amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (1-42), human TFA (Biotin-Amyloid β-Peptide (1-42) (human) TFA) is the botin labeled β-Amyloid (1-42), human TFA (HY-P1363). β-Amyloid (1-42), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P3688A

β-Amyloid (1-38) TFA Aβ (1-38) TFA; Aβ38 TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .

HY-103374

Phenserine (-)-Eseroline phenylcarbamate; (-)-Phenserine	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .

HY-P1388A

β-Amyloid (1-42), (rat/mouse) TFA 5+ Cited Publications amyloid β-peptide (1-42) (rat/mouse) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P10040

(Gln22)β-Amyloid (1-40) human	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P1046

β-Amyloid (1-15) amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P2550A

β-Amyloid (1-40), FAM-labeled TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40), FAM-labeled TFA is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λex= 492 nm and λem= 518 nm).

HY-P1387

β-Amyloid (1-40) (rat)	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca ²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .

HY-P1362F

Cy5-β-Amyloid (42-1), human Tris Cy5-amyloid β Peptide (42-1)(human) Tris	Amyloid-β	Neurological Disease
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

HY-P5905

*Citrullinated amyloid-β (1-42) peptide* (human)** Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-B1588

Carbenoxolone 5+ Cited Publications	Amyloid-β Gap Junction Protein	Neurological Disease Metabolic Disease
Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis .

HY-P1468

β-Amyloid (1-28) amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P2550

β-Amyloid (1-40), FAM-labeled	Amyloid-β	Neurological Disease
β-Amyloid (1-40), FAM-labeled is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λ_ex= 492 nm and λ_em= 518 nm) .

HY-P1891

β-Amyloid (22-40)	Amyloid-β	Neurological Disease
β-Amyloid (22-40) is a peptide fragment of β-Amyloid.

HY-P1363S

β-Amyloid-15N (1-42), human TFA amyloid β-peptide-15N (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P3688

β-Amyloid (1-38) Aβ (1-38); Aβ38	Amyloid-β	Neurological Disease
β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .

HY-P1517

β-Amyloid (31-35)	Amyloid-β	Neurological Disease
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

HY-P1894

β-Amyloid Protein Precursor 770 (135-155)	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P1879

β-Amyloid (18-28)	Amyloid-β	Neurological Disease
β-Amyloid (18-28) is a peptide fragment of β-Amyloid.

HY-P1051

β-Amyloid (12-28) amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P1522

β-Amyloid (29-40) amyloid beta-protein(29-40)	Amyloid-β	Neurological Disease
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1362A

β-Amyloid (42-1), human TFA amyloid β Peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1053

β-Amyloid (10-20)	Amyloid-β	Neurological Disease
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease .

HY-P10040A

(Gln22)β-Amyloid (1-40) human TFA	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) (human) TFA is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P2562

β-Amyloid (1-38), mouse, rat	Amyloid-β	Neurological Disease
β-Amyloid (1-38), mouse, rat is composed of 38 aa (1-38 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1894A

β-Amyloid Protein Precursor 770 (135-155) TFA	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) TFA is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

HY-P11226

TI-16	Amyloid-β CaMK Apoptosis	Neurological Disease
TI-16 is a peptide that targets β-amyloid (Aβ) protein. TI-16 can cross the blood-brain barrier. TI-16 can increase the concentration of intracellular free CaM, thereby restoring calcium ion homeostasis and reducing Aβ toxicity. TI-16 can reduce the deposition of Aβ in the brain, improve neuronal pathology, inhibit cell apoptosis, and improve cognitive function in mice. TI-16 is commonly used in the study of Alzheimer's disease .

HY-P10628

β Amyloid (1-14), human	Amyloid-β	Neurological Disease
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .

HY-P5968A

[Ala28]-β Amyloid(25-35) TFA β(25-35)KA TFA	Amyloid-β	Neurological Disease
[Ala28]-β Amyloid(25-35) (β(25-35)KA) TFA is an electrically neutral mutant peptide of Aβ(25-35) that accelerates the aggregation of Firefly Luciferase .

HY-P1880

β-Amyloid (12-20)	Amyloid-β	Neurological Disease
β-Amyloid (12-20) is a peptide fragment of β-Amyloid.

HY-P1893

β-Amyloid (11-22)	Amyloid-β	Neurological Disease
β-Amyloid (11-22) is a peptide fragment of β-Amyloid.

HY-P1867

β-Amyloid (1-34)	Amyloid-β	Neurological Disease
β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.

HY-P1772

β-Amyloid (1-17)	Amyloid-β	Neurological Disease
β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation .

HY-P1895

β-Amyloid (33-40)	Amyloid-β	Neurological Disease
β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.

HY-P1898

β-Amyloid (13-27)	Amyloid-β	Neurological Disease
β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.

HY-P10039

β Amyloid (1-16) rat	Amyloid-β	Neurological Disease
β-Amyloid (1-16) rat is a β-amyloid peptide (Abeta), a metal-binding domain fragment of amyloid. Three amino acid substitutions in β-Amyloid (1-16) rat that differ from humans render rats and mice less susceptible to AD-like neurodegeneration .

Cat. No.	Product Name	Type

HY-P1363F3

5-FAM-β-Amyloid (1-42), human Tris 5-FAM-amyloid β-peptide (1-42) (human) Tris	Fluorescent Dyes
5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).

HY-P1362F

Cy5-β-Amyloid (42-1), human Tris Cy5-amyloid β Peptide (42-1)(human) Tris	Fluorescent Dyes
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N13064

2,2′,4,4′-Tetrahydroxychalcone	Structural Classification Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Drug Derivative Beta-secretase Amyloid-β
2,2′,4,4′-Tetrahydroxychalcone (Compound 18) is a selective and potent BACE1 inhibitor with an IC₅₀ of 0.62 μM. 2,2′,4,4′-Tetrahydroxychalcone is a derivative of Isoliquiritigenin (HY-N0102) found in Glycyrrhiza uralensis. 2,2′,4,4′-Tetrahydroxychalcone can block the β-cutting step of amyloid precursor protein (APP), thereby reducing the production of *β-amyloid* (Aβ) peptide. 2,2′,4,4′-Tetrahydroxychalcone can be used for research of Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-P1363S

β-Amyloid-15N (1-42), human TFA
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

Cat. No.	Product Name		Classification

HY-175524

BChE/MAO-B-IN-2		Alkynes
BChE/MAO-B-IN-2 is a dual inhibitor of BChE (IC₅₀ = 0.05 μM, K_i = 0.01 μM) and MAO-B (IC₅₀ = 0.45 μM, K_i = 0.08 μM) with good blood-brain barrier permeability. BChE/MAO-B-IN-2 exhibits antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. BChE/MAO-B-IN-2 can be used for the study of Alzheimer's disease (AD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks